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Abstract. 
 
 
 
-Catenin is a protein that plays a role in in-
tercellular adhesion as well as in the regulation of gene
expression. The latter role of 
 
 
 
-catenin is associated with
its oncogenic properties due to the loss of expression or
inactivation of the tumor suppressor adenomatous pol-
yposis coli (APC) or mutations in 
 
 
 
-catenin itself. We
now demonstrate that another tumor suppressor, PTEN,
is also involved in the regulation of nuclear 
 
 
 
-catenin
accumulation and T cell factor (TCF) transcriptional
activation in an APC-independent manner. We show
that nuclear 
 
 
 
-catenin expression is constitutively ele-
vated in PTEN null cells and this elevated expression is
reduced upon reexpression of PTEN. TCF promoter/lu-
ciferase reporter assays and gel mobility shift analysis
demonstrate that PTEN also suppresses TCF transcrip-
tional activity. Furthermore, the constitutively elevated
expression of cyclin D1, a 
 
 
 
-catenin/TCF–regulated gene,
is also suppressed upon reexpression of PTEN. Mecha-
nistically, PTEN increases the phosphorylation of 
 
 
 
-cate-
nin and enhances its rate of degradation. We deﬁne a
pathway that involves mainly integrin-linked kinase and
glycogen synthase kinase 3 in the PTEN-dependent regu-
lation of 
 
 
 
-catenin stability, nuclear 
 
 
 
-catenin expres-
sion, and transcriptional activity. Our data indicate that
 
 
 
-catenin/TCF–mediated gene transcription is regu-
lated by PTEN, and this may represent a key mecha-
nism by which PTEN suppresses tumor progression.
Key words: integrin-linked kinase • glycogen syn-
thase kinase 3 • cyclin D1 • prostate cancer • protein
kinase B
 
Introduction
 
 
 
-Catenin was originally identified as a cytoplasmic com-
ponent of cell–cell adherens junctions, where it interacts
with the cytoplasmic domains of cadherin molecules and
links them via 
 
 
 
-catenin to the actin cytoskeleton (Kemler,
1993; Geiger et al., 1995). 
 
 
 
-Catenin is also part of the 
 
wnt
 
-
signaling pathway (Peifer and Wieschaus, 1990; Peifer et
al., 1993; Wodarz and Nusse, 1998). Upon stimulation of
this pathway, 
 
 
 
-catenin accumulates in the cytoplasm and
subsequently translocates to the nucleus in association
with members of the T cell factor (TCF)
 
1
 
/lymphoid en-
hancer factor (LEF) DNA-binding transcription factor fam-
ily (Miller and Moon, 1996; Willert and Nusse, 1998). In the
nucleus, this bipartite complex binds to DNA at the TCF/
LEF binding sites and induces the transcription and expres-
sion of specific genes (Riese et al., 1997; van de Wetering et
al., 1997). The cyclin D1 gene has been identified as a key
transcriptional target of 
 
 
 
-catenin/TCF through a TCF-4/
LEF-1 binding site in the cyclin D1 promoter (Shtutman et
al., 1999; Tetsu and McCormick, 1999; Behrens, 2000; Lin et
al., 2000). In addition to cyclin D1, two other recently de-
fined targets, 
 
c-myc
 
 and matrilysin, may also be responsible
for the oncogenic potential of 
 
 
 
-catenin (He et al., 1998;
Brabletz et al., 2000). In the absence of growth and differen-
tiation signals, cytoplasmic 
 
 
 
-catenin is efficiently degraded
by the ubiquitin-proteosome system (Aberle et al., 1997; Or-
ford et al., 1997; Salomon et al., 1997). Protein degradation
by the proteosome is under the control of the adenomatous
polyposis coli (APC), glycogen synthase kinase 3 proteins
(GSK-3; Munemitsu et al., 1995; Rubinfeld et al., 1996), and
adapter proteins axin and conductin (Behrens, 2000; Po-
lakis, 2000). The process involves targeted phosphorylation
of highly conserved serine and threonine residues (Yost et
al., 1996) and ubiquitination of the NH
 
2
 
 terminus of 
 
 
 
-cate-
nin (Aberle et al., 1997; Orford et al., 1997). Mutation of
these NH
 
2
 
 terminus phosphorylation sites of 
 
 
 
-catenin stabi-
lize the protein, promote its nuclear accumulation, and
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hence its availability to serve as a transcription factor (Yost
et al., 1996; Korinek et al., 1997; Morin et al., 1997; Barker et
al., 2000). Loss of functional APC protein also results in sta-
bilization and accumulation of 
 
 
 
-catenin, leading to subse-
quent dysregulation of the signaling pathway (Munemitsu et
al., 1995; Tetsu and McCormick 1999). Dysregulation of
 
 
 
-catenin signaling due to loss of APC or mutations in
 
 
 
-catenin itself is an important event in the progression of
colorectal cancer (Voeller et al., 1998; Morin, 1999). Al-
though increased nuclear 
 
 
 
-catenin accumulation and TCF
activity are frequently found in other malignancies, for ex-
ample prostate cancers, 
 
 
 
-catenin mutations (Voeller et
al., 1998) or APC mutations (Suzuki et al., 1994; Watanabe et
al., 1996) do not appear to be involved in this activation.
A very frequent and prominent feature of prostate can-
cer (as well as a wide variety of other human cancers) is
the mutational inactivation of the tumor suppressor PTEN
(Stambolic et al., 1998; Sun et al., 1999). PTEN is a lipid
and protein phosphatase that is a negative regulator of
phosphatidylinositol 3 (PI-3) kinase–dependent signaling
pathway. The latter regulates cell survival and growth via
integrated signaling from growth factor receptors and
components of the extracellular matrix (Stambolic et al.,
1998; Sun et al., 1999). Loss of expression or mutational in-
activation of PTEN results in the suppression of apoptosis
(Stambolic et al., 1998) and accelerated cell cycle progres-
sion (Ramaswamy et al., 1999; Sun et al., 1999). Reexpres-
sion of PTEN in PTEN null cells has been shown to induce
growth suppression (Ramaswamy et al., 1999; Sun et al.,
1999) and this is thought to be mediated by the inhibition
of signaling through the PI-3 kinase pathway (Ramaswamy
et al., 1999; Sun et al., 1999). We have also recently dem-
onstrated that reexpression of PTEN induced apoptosis
and G1 cell cycle arrest in PTEN null prostate cancer
cells (Persad et al., 2000). Although the exact biochemi-
cal mechanisms by which PTEN exerts its growth inhibi-
tory effects are still largely unknown, it has been shown
that PI-3 kinase and PTEN regulate the phosphoryla-
tion, and hence activation, of the antiapoptotic protein,
protein kinase B (PKB; Ramaswamy et al., 1999; Sun et
al., 1999). We have recently shown that the integrin-linked
kinase (ILK) is an intermediate between PTEN and PKB,
such that inhibition of ILK activity also results in the inhi-
bition of activation of PKB and in an increase in apoptosis
and G1 phase cell cycle arrest (Persad et al., 2000).
In this study, we demonstrate that in the absence of any
overt APC (Suzuki et al., 1994; Watanabe et al., 1996) or
 
 
 
-catenin (Voeller et al., 1998) mutations, the PTEN null
prostate cancer cell lines PC3 and LNCaP exhibit constitu-
tively high levels of nuclear 
 
 
 
-catenin, as well as cyclin D1.
Upon reexpression of wild-type PTEN (PTEN-WT),
GSK-3 activity is increased, leading to an increase in 
 
 
 
-cat-
enin phosphorylation, increased 
 
 
 
-catenin degradation,
and subsequent decrease in the expression of the protein
in the nucleus. Transfection of PC3 cells with the domi-
nant negative form of ILK (kinase-deficient ILK [ILK-
KD]) or GSK-3-WT also suppressed the elevated expres-
sion of nuclear 
 
 
 
-catenin. Furthermore, PTEN, ILK-KD,
and GSK-3-WT induced comparable suppression of TCF/
 
 
 
-catenin transcriptional activity in PC3 cells. In correla-
tion with this, we noted that cyclin D1 expression and pro-
moter activity, which are constitutively elevated in PC3
 
cells, are suppressed upon reexpression of PTEN or ex-
pression of ILK-KD and GSK-3-WT. These results delin-
eate a novel role for PTEN in the regulation of cell growth
and proliferation via its regulation of nuclear 
 
 
 
-catenin
and subsequently cyclin D1.
 
Materials and Methods
 
Cell Culture and Transfections
 
The PTEN null prostate cancer cell lines PC3 and LNCaP were used in
this study. PC3 cells were cultured in DME containing 10% FBS, and LN-
CaP cells were cultured in RPMI-1640 media supplemented with 10%
FBS. All cells were passaged in 5% CO
 
2
 
 at 37
 
 
 
C. The cells were tran-
siently transfected with His-V
 
5
 
–tagged ILK-WT cDNA, His-V
 
5
 
–tagged
ILK-KD cDNA, green fluorescent protein (GFP)-tagged PTEN-WT
cDNA (Persad et al., 2000), GFP-tagged pEGFP cDNA, hemagglutinin
(HA)-tagged dominant negative PKB (PKB-AAA) cDNA (Wang et al.,
1999) or HA-tagged GSK-3-WT cDNA. Transfection of PC3 and LNCaP
cells was carried out by using lipofectin reagent (GIBCO BRL) according
to the manufacturers guidelines, and using 4 
 
 
 
l of lipofectin reagent and
2–8 
 
 
 
g cDNA. Control cells were transfected with an empty vector. The
ILK cDNAs, PKB-AAA cDNA, and GSK-3 cDNA were in the pc-DNA-3
plasmid, whereas the PTEN cDNA was in the p-EGFP plasmid. The effi-
ciency of the transfections were evaluated by flow cytometric analysis of
cells cotransfected with pEGFP cDNA and the various plasmids used in
the study. The PTEN plasmid is tagged with GFP and therefore was not
cotransfected with pEGFP. The percentage of cells expressing GFP was
then evaluated using the WinMDI analysis program. All transfections
were carried out overnight and the cells were processed for immunofluo-
rescence or harvested for lysis 24–48 h later.
 
Western Blot
 
Equivalent protein concentrations were resolved by SDS-PAGE electro-
phoresis and proteins were transferred to polyvinylidene difluoride mem-
brane. Western blot analysis using the enhanced chemiluminescence de-
tection system (Amersham Pharmacia Biotech) was carried out as
described previously (Delcommenne et al., 1998). The following antibod-
ies were used in this study: anti–
 
 
 
-catenin antibody (mouse monoclonal;
Transduction Laboratories), anti–
 
 
 
-catenin antibody (rabbit polyclonal;
Santa Cruz Biotechnology, Inc.), N-cadherin (mouse monoclonal), anti–
TCF-4 antibody (mouse monoclonal; Upstate Biotechnology), anti–Lef-1
antibody (mouse monoclonal; Oncogene Research Products); anti-His-
tone H1 antibody (mouse monoclonal; Chemicon International, Inc.);
anti-GFP antibody (mouse monoclonal; Boehringer); anti-Cyclin D1
(mouse monoclonal; Upstate Biotechnology), anti-p27
 
Kip
 
 (rabbit poly-
clonal; Upstate Biotechnology), anti-p21
 
Cip
 
 (rabbit polyclonal; Upstate
Biotechnology), anti-ILK antibody (rabbit polyclonal; StressGen Biotech-
nologies), anti-PTEN antibody (mouse monoclonal; Oncogene Research
Products), anti-PKB antibody (rabbit polyclonal; New England Biolabs,
Inc.), anti–GSK-3 antibody (mouse monoclonal; Transduction Laborato-
ries); antiphospho–
 
 
 
-catenin (Ser33/37/Thr41) antibody (rabbit poly-
clonal; Cell Signaling Technologies).
 
Cells and Fluorescence Microscopy
 
PC3 cells were plated onto Lab-Tek
 
®
 
 chamber slides (Nunc) 24 h before
transfection. Cells were transfected overnight with PTEN-GFP (3 
 
 
 
g) us-
ing Lipofectin reagent (4 
 
 
 
l) according to the manufacturers guidelines.
Cells were fixed and permeabilized 48 h posttransfection with methanol at
 
 
 
20
 
 
 
C for 20 min. Immunofluorescence analysis was done using mouse
monoclonal 
 
 
 
-catenin antibody followed by rhodamine (TRITC)-conju-
gated anti–mouse IgG (Jackson ImmunoResearch Laboratories). Images
were obtained by fluorescent microscopy (ZEISS). The percentage of
cells with nuclear 
 
 
 
-catenin was determined by evaluating the number of
cells expressing high amounts of nuclear 
 
 
 
-catenin in a field with refer-
ence to the total number of cells in that field.
 
Luciferase Assay for TCF and Cyclin 
D1 Promoter Activities
 
Luciferase assays were done according to the manufacturer’s instructions
(Promega). A dual luciferase reporter assay was performed whereby the 
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experimental TCF promoter/luciferase reporter gene (TOPFLASH; Ko-
rinek et al., 1997) or the cyclin D1 promoter/luciferase reporter (Tetsu
and McCormick, 1999) and a control reporter (
 
pRenilla
 
) were cotrans-
fected with ILK-WT, ILK-KD, PTEN-WT, PKB-AAA, or GSK-3-WT.
The effect of ILK-WT, ILK-KD, PTEN-WT, PKB-AAA, or GSK-3-WT
upon the TCF reporter gene activity and the effect of ILK-WT, ILK-KD,
PTEN-WT, or GSK-3-WT on cyclin D1 reporter gene activity were evalu-
ated. The promoter activity was normalized to the activity of the control
(
 
pRenilla
 
). Two different TCF-luciferase reporter genes were used in this
study: an intact wild-type TCF-luciferase reporter construct (TOP-
FLASH) and a mutated TCF-luciferase reporter construct (FOPFLASH),
which served as a negative control for TOPFLASH activity. Protein con-
centrations were determined by Bradford assay and the results were ex-
pressed as relative light units per microgram of protein.
 
Nuclear Extracts and Electrophoretic 
Mobility Shift Assays
 
Nuclear extracts were prepared by the miniextraction method as described
previously (Andrews and Faller, 1991). PC3 cells transfected with empty
vector (control), ILK-KD, or PTEN-WT were washed with ice cold PBS
and harvested by being scraped in 1.5 ml PBS. Cells were then pelleted and
resuspended in 400 
 
 
 
l of 10 mM Hepes–potassium hydroxide, pH 7.9, 1.5
mM magnesium chloride, 10 mM potassium chloride, 0.5 mM dithiothrei-
tol, 0.2 mM PMSF. After 10 min of incubation on ice, nuclei were pelleted
by being spun for 10 s and resuspended in 50 
 
 
 
l of 20 mM Hepes–potas-
sium hydroxide, pH 7.9, 25% glycerol, 420 mM sodium chloride, 1.5 mM
magnesium chloride, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.2 mM
PMSF. Tubes were incubated for 20 min on ice and then centrifuged to
clear the cellular debris. Nuclear extracts were stored at 
 
 
 
70
 
 
 
C. Electro-
phoretic mobility shift assays were performed by using 4 
 
 
 
g of the nuclear
extracts for 20 min at room temperature with a 
 
32
 
P end-labeled DNA frag-
ment containing the putative protein binding site (for TCF binding site
from CD1 promoter, 5
 
 
 
-TGC CGG GCT TTG ATC TTT GCT-3
 
 
 
; [
 
 
 
-
 
32
 
P]ATP was from Amersham Pharmacia Biotech). Reaction products
were analyzed on a nondenaturing 5% polyacrylamide gel (0.5% Tris-bo-
rate-EDTA, 3.5% glycerol). The specificity of the DNA–protein interac-
tion was established by competition experiments using 10
 
 
 
 cold TCF oli-
gonucleotide as the competitor. For the supershift assays, 10 
 
 
 
g of mouse
anti–
 
 
 
-catenin antibody or nonspecific IgG was added to the reaction mix-
ture, subsequent to the addition of the 
 
32
 
P-labeled oligonucleotide probe,
and the mixture was incubated for 45 min at room temperature. Complexes
were resolved by electrophoresis as described for the mobility shift assays.
 
Nuclear Extracts and Coimmunoprecipitation Assay
 
PC3 cells were transfected with an empty vector (control), ILK-KD, or
PTEN-WT cDNA and harvested at 48 h posttransfection. The cells were
washed in cold PBS and nuclear extracts were prepared by the miniextrac-
tion method as described previously (Andrews and Faller, 1991). Immu-
noprecipitation of 
 
 
 
-catenin was performed using 400 
 
 
 
g of nuclear lysate
and polyclonal anti–
 
 
 
-catenin antibody. Immunocomplexes were isolated
with protein A/G-PLUS agarose (Santa Cruz Biotechnology, Inc.) and
separated on 7.5% SDS-PAGE gels. The gels were then Western blotted
with either monoclonal anti–TCF-4 or monoclonal anti–Lef-1 antibodies
to detect presence of these transcription factors in the immunocomplexes.
 
Pulse–Chase Analysis
 
PC3 cells were cultured to 70–80% confluence and transfected with empty
vector (control) or PTEN-WT. For each chase time point the cells were
washed once with DME without cysteine/methionine (starve media;
Sigma-Aldrich) and incubated in the starve media for 1 h at 37
 
 
 
C. Cells
were pulsed for 1 h at 37
 
 
 
C using [
 
35
 
S]Promix (Amersham Pharmacia Bio-
tech), 100 
 
 
 
Ci/ml. Cells were then chased with DME/10% FBS for the in-
dicated time points. The cells were harvested at the various time points
and lysed in RIPA buffer. Immunocomplexes were isolated with protein
G Sepharose (Santa Cruz Biotechnology, Inc.) and separated on 7.5%
SDS-PAGE gels, stained with Coomassie blue, destained, and incubated
with Amplify (Amersham Pharmacia Biotech) fluorographic reagent,
dried, and exposed to film.
 
Northern Blot Analysis of Cyclin D1
 
Northern blot analysis of cyclin D1 was carried out on total RNA from se-
rum-starved PC3 cells. Total RNA was isolated from in vitro cultured PC3
 
cells using TRIZOL reagent (Life Technologies). The PC3 cells were
transfected with empty vector (control), ILK-WT, ILK-KD, PTEN-WT,
or GSK-3-WT. 15 
 
 
 
g of total RNA from each sample was subjected to
electrophoresis on 1.2% agarose-formaldehyde gels and transferred to ny-
lon membranes (Gelman Sciences) overnight. The RNA blots were hy-
bridized with a cyclin D1 cDNA probe labeled with [
 
32
 
P]dCTP by random
primer labeling.
 
GSK-3 Kinase Assay
 
GSK-3 kinase activity was determined in cell extracts from PC3 cells tran-
siently transfected with either empty vector (control), ILK-WT, ILK-KD,
PTEN-WT or dominant negative PKB (PKB-AAA). Cells were lysed in
50 mM Hepes buffer, pH 7.5, containing NaCl (150 mM), NP-40 (1%), so-
dium deoxycholate (0.5%), leupeptin (10 
 
 
 
g/ml), PMSF (1 mM), aproti-
nin (2.5 
 
 
 
l/ml), sodium fluoride (5 mM) and sodium orthovanadate (1
mM). Equivalent protein concentrations of cell lysates (determined by
Bradford Assay) were precleared with nonspecific IgG and protein A
Sepharose. After centrifugation the supernatants were immunoprecipi-
tated with anti–GSK-3
 
 
 
 antibody bound to protein A Sepharose beads.
Kinase assay was carried out as described previously (Delcommenne et
al., 1998) using GS-1 peptide as a substrate. Phosphorylated GS-1 peptide
was electrophoresed on a tricine gel, then visualized and quantified by au-
toradiography or phosphoimage analysis.
 
ILK Kinase Assay
 
Equivalent protein concentrations of cell lysates were precleared with
nonspecific IgG and protein A Sepharose. After centrifugation, the super-
natants were immunoprecipitated with anti-ILK antibody (Upstate Bio-
technology) bound to protein A Sepharose. Kinase assays were carried
out as described previously (Delcommenne et al., 1998) using purified
GSK-3-KD as substrate and [
 
 
 
-
 
32
 
P]ATP as the phosphate donor. The ILK
kinase assays were carried out in the presence or absence of either DMSO
or a highly selective small molecule inhibitor of ILK, KP-SD-1 (Persad et
al., 2001). Phosphorylated GSK-3 was electrophoresed on a 7.5% SDS-
PAGE gel, then visualized and quantified by autoradiography and phos-
phoimage analysis.
In addition, in vitro ILK kinase assays were carried out in which puri-
fied recombinant ILK prepared in insect cells and GSK-3-KD were coin-
cubated in the presence of kinase reaction buffer and ATP as described
previously (Delcommenne et al., 1998). The kinase assays were carried
out in the presence or absence of the ILK inhibitor, KP-SD-1. Phosphory-
lated GSK-3 was resolved by SDS-PAGE and detected by Western blot
analysis using the anti–GSK-3-Ser-9-P antibody (rabbit polyclonal; New
England Biolabs, Inc.).
 
Results
 
Inhibition of Nuclear 
 
 
 
-Catenin Expression and 
Induction of E-Cadherin Expression in 
PTEN-negative Cells by Reexpression of PTEN
 
Upon examination of 
 
 
 
-catenin expression in prostate
cancer cell lines, we noted that a significant population of
the PTEN-negative prostate cancer cells (PC3; 
 
 
 
70%) ex-
press high levels of 
 
 
 
-catenin in the nucleus (Fig. 1 A).
Constitutively high levels of 
 
 
 
-catenin are also observed in
nuclear extracts from PC3 cells as well as another PTEN
null prostate cancer cell line, LNCaP (Fig. 1, B and C).
Transient transfection of increasing amounts of PTEN-
WT into these PTEN null cells (LNCaP and PC3) leads to
inhibition of nuclear 
 
 
 
-catenin expression in these cells
(Fig. 1, B and C). The transfection efficiency of the PTEN-
WT plasmid is 
 
 
 
80% in PC3 and LNCaP prostate cancer
cells. There was no change in nuclear 
 
 
 
-catenin expression
when PC3 cells were transfected with increasing amounts
of pEGFP cDNA (Fig. 1 C). Total cellular 
 
 
 
-catenin ex-
pression was unaffected by the PTEN transfections. Im-
munofluorescence microscopy of PC3 cells transiently 
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Figure 1. Expression of nuclear  -catenin is reduced by reex-
pression of PTEN in PTEN null prostate cancer cells. (A) Immu-
nofluorescence analysis of PTEN null prostate cancer cells, PC3,
shows that a significant population (70%) of these cells express
high levels of  -catenin in their nucleus (arrowheads). Reexpres-
sion of PTEN in PTEN null prostate cancer cells LNCaP (B) and
PC3 (C) results in a dose-dependent reduction in the expression
of nuclear  -catenin. (D) Immunofluorescence analysis of  -cate-
nin confirms that unlike nontransfected PC3 cells (arrowheads),
PC3 cells transfected with PTEN (arrows) exhibit anuclear local-
ization  -catenin. A significantly lower proportion of cells in this
case express high levels of nuclear  -catenin (16%). Bar, 5  m. 
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transfected with PTEN-GFP also showed that 
 
 -catenin is
mostly present outside the nucleus in cells expressing
PTEN-GFP, and a much smaller number of cells ( 16%)
express nuclear  -catenin (Fig. 1 D). Surprisingly, reex-
pression of PTEN also induced the expression of E-cad-
herin in PC3 cells, which do not normally express E-cad-
herin (Fig. 1 C). However, PC3 cells do express N-cadherin
and the expression of this cadherin remains unchanged by
the reexpression of PTEN (Fig. 1 C).
Constitutive Expression of Nuclear  -Catenin in PC3 Cells 
Is Reduced by Dominant Negative ILK and GSK-3-WT
To identify a pathway via which PTEN may be regulating
 -catenin, we investigated the effect of the various mem-
bers of the pathway downstream of PI-3 kinase/PTEN,
namely, ILK, PKB, and GSK-3, on nuclear  -catenin ex-
pression (Fig. 2). GSK-3 is known to be a member of the
complex that regulates cellular levels of  -catenin in a
phosphorylation-dependent manner (Morin, 1999; Beh-
rens, 2000).
We have recently demonstrated a critical role for the
ILK in PTEN-dependent cell cycle regulation (Persad et
al., 2000). Also, ILK has been shown to inhibit GSK-3 ac-
tivity upon cell–extracellular matrix interaction (Trous-
sard et al., 1999). In this study we show that although tran-
sient transfection of ILK-WT has no effect on nuclear
 -catenin expression, expression of the dominant negative
ILK (Persad et al., 2000) or GSK-3-WT resulted in signifi-
cant reductions in nuclear  -catenin expression (Fig. 2).
The dramatic inhibitory effects of the plasmids are a re-
flection of their high transfection efficiency (ILK-KD,
79%; GSK-3, 78%) into PC3 cells. Since dominant nega-
tive ILK has been shown to inhibit PKB serine 473 phos-
phorylation and its activity in PC3 cells, we wanted to
determine whether the ILK-KD– and PTEN-induced inhi-
bition of nuclear  -catenin involved PKB activity. Surpris-
ingly, even though the transfection efficiency of PKB-
AAA is quite comparable (79%) to the other plasmids, we
found that its effect upon nuclear  -catenin expression
was lower compared with dominant negative ILK, PTEN-
WT, or GSK-3-WT. Total cellular levels of  -catenin re-
mained unchanged by all the plasmid transfections.
The results in Fig. 2 suggest that PTEN suppresses nu-
clear accumulation of  -catenin and this involves the
downstream effectors, ILK and GSK-3, and to a lesser ex-
tent, PKB.
Expression of PTEN or Inhibition of ILK Inhibits Complex 
Formation between  -Catenin and TCF and between
 -Catenin/TCF and TCF Consensus Oligonucleotide
It is known that  -catenin interacts with transcription fac-
tors of the TCF/LEF family and subsequently activates
genes that are responsive to TCF/LEF family members
(Giese et al., 1995; Behrens et al., 1996; Clevers and Gross-
chedl, 1996; Molenaar et al., 1996; van de Wetering et al.,
1997). Therefore, we analyzed the ability of  -catenin to
form complexes with a TCF-4 consensus oligonucleotide
in the presence of either PTEN-WT or dominant negative
ILK. PC3 cells were transfected with empty vector, PTEN-
WT, or ILK-KD, and nuclear extracts for gel mobility shift
assays were prepared. The gel mobility shift assay demon-
strated the presence of significant levels of protein–DNA
complex in PC3 cells transfected with empty vector (Fig. 3
A, panel 1). However, the level of the protein–DNA com-
plex was significantly reduced in PC3 cells transfected with
either PTEN-WT or ILK-KD (lanes 2 and 3) compared
with cells transfected with empty vector (lane 1).
To determine if the protein–DNA complex in the PC3
cells contained  -catenin, we carried out a supershift assay
using anti– -catenin antibody to detect the presence of
 -catenin in the complex. As seen in Fig. 3 A, panel 2,
anti– -catenin antibody induced a protein–DNA mobility
shift of the complex, highlighting the presence of  -catenin
in the complex. In agreement with the reduced levels of
protein–DNA complex in PC3 cells transfected with
PTEN-WT or ILK-KD, the supershift bands, while quite
evident in the empty vector–transfected cells (panel 2, lane
1), were negligible to absent in PTEN or ILK-KD–trans-
fected cells (panel 2, lanes 2 and 3). Furthermore, Western
blot analysis of nuclear  -catenin immunoprecipitates with
anti–TCF-4 or anti–Lef-1 antibodies identified substan-
tially reduced  -catenin–TCF-4 and  -catenin–Lef-1 com-
plexes in ILK-KD– and PTEN-WT–transfected PC3 cells
compared with controls (Fig. 3 B).
Figure 2. Nuclear   -catenin is mainly regulated by PTEN and
ILK via GSK-3. The expression of nuclear  -catenin is dramati-
cally and comparably abrogated by expression of PTEN (82%),
ILK-KD (79%), and GSK-3-WT (78%) into PC3 cells. Nuclear
 -catenin expression is altered to a lesser extent by the dominant
negative PKB-AAA (79%) and completely unaffected by expres-
sion of ILK-WT (78%).Values in brackets indicate the transfection
efficiency of the various plasmids. The absence of any alterations in
the total cellular  -catenin expression demonstrates the specific
effect of the various components upon nuclear  -catenin. The Journal of Cell Biology, Volume 153, 2001 1166
In view of the fact that the nuclear  -catenin is com-
plexed to TCF and likely induces the activity of genes con-
taining a TCF DNA binding site in their promoter region,
our next aim was to determine the effect of the various
members of the PI-3 kinase/PTEN pathway (PTEN, ILK,
PKB, and GSK-3) upon this  -catenin–mediated transacti-
vation. A multimeric synthetic TCF-4 binding site up-
stream of a luciferase reporter gene (TOPFLASH; van de
Wetering et al., 1997) was cotransfected into PC3 cells to-
gether with either ILK-WT, ILK-KD, PTEN-WT, PKB-
AAA, or GSK-3-WT cDNAs. Parallel experiments, where
each of the experimental cDNAs were cotransfected into
PC3 cells with a construct containing a mutated TCF-4
binding site upstream of a luciferase reporter gene (FOP-
FLASH) served as a negative control. The results pre-
sented in Fig. 3 C show a dramatic decrease (75–80%) in
luciferase activity due to transfection and expression of
PTEN-WT, ILK-KD, or GSK-3-WT into PC3 cells. Inter-
estingly, the inhibition of TOPFLASH activity due to
transfection of PKB-AAA was much lower (25%).
Collectively, the results in Fig. 3 show that in PTEN null
cells  -catenin likely accumulates in the nucleus in com-
plex with TCF/LEF. The  -catenin–TCF–LEF bipartite
complex binds to TCF DNA response element and in-
duces genes that possess the TCF DNA binding site in
their promoter region. In the presence of dominant nega-
tive ILK or upon reexpression of PTEN,  -catenin accu-
mulation in the nucleus is inhibited, resulting in a decrease
in transcription of target genes. The results also suggest
that PTEN regulates  -catenin–TCF–LEF-mediated tran-
scriptional activity via ILK and GSK-3, with a smaller con-
tribution from PKB.
GSK-3 Activity Is Stimulated by PTEN-WT and 
Dominant Negative ILK in PTEN Null Cells
To further understand the relative roles of ILK and PTEN
in the GSK-3–mediated regulation of  -catenin, we evalu-
ated GSK-3 activity in PC3 cells transiently transfected
with ILK-WT, ILK-KD, PKB-AAA, or PTEN-WT. As
shown in Fig. 4 A, although both PTEN-WT and dominant
negative ILK-KD induced a significant increase in GSK-3
activity ( 3–4-fold) the effect of dominant negative PKB-
AAA was lower ( 1.6-fold). This difference is unlikely to
be due to differences in transfection efficiencies, since all
three plasmids had comparable transfection efficiencies
(see legend to Fig. 4). Transfection of ILK-WT cDNA did
not alter the activity of GSK-3 compared with the control.
Figure 3. PTEN and ILK-KD inhibit DNA binding activities of  -catenin–TCF complex. (A)
Electrophoretic mobility shift assays, using an oligonucleotide containing a potential binding site
for TCF, demonstrated an abundance of DNA–protein complex in empty vector–transfected PC3
cells (panel 1, lane 1). The quantities of the protein–DNA complex are reduced significantly in
PC3 cells transfected with ILK-KD or PTEN (panel 1, lanes 2 and 3). Electrophoretic mobility
shift assays performed in the presence of a supershifting antibody (anti– -catenin antibody) con-
firmed that the transcription factor complex binding to the oligonucleotide includes  -catenin
(panel 2). (B) Coimmunoprecipitation of TCF-4 or Lef-1 with  -catenin using nuclear lysates from
empty vector (control), ILK-KD–, or PTEN-WT–transfected PC3 cells show reduced complex for-
mation in ILK-KD– and PTEN-WT–transfected cells compared with control cells. (C) The relative
 -catenin/TCF activities (TOPFLASH/FOPFLASH luciferase reporter) in response to the various
components of the PI-3 kinase/PTEN pathway. PC3 cells were transiently transfected with 0.5  g
of TOPFLASH reporter together with 2.5  g of empty vector, ILK-WT, ILK-KD, PTEN-WT, PKB-AAA, or GSK-3-WT.  -Catenin/
TCF activity was dramatically reduced due to PTEN, ILK-KD, and GSK-3-WT. The effect of PKB-AAA upon TOPFLASH activity was
more modest in comparison. Parallel cotransfections with the various plasmids and FOPFLASH served as a negative control for TOP-
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These data confirm that GSK-3 activity, which is known to
be involved in controlling  -catenin levels in cells (Morin,
1999; Behrens, 2000), is regulated to various extents by
PTEN, ILK, and PKB. Although both ILK (Delcom-
menne et al., 1998; Troussard et al., 1999) and PKB (Cross
et al., 1995) are known to phosphorylate GSK-3, the
greater stimulatory effect of PTEN and ILK-KD upon
GSK-3 activity compared with PKB-AAA indicate that in
these cells, GSK-3 is largely regulated by PTEN in an ILK-
dependent manner. The critical protein in the regulation of
 -catenin phosphorylation and stability is GSK-3, whose
activity is also regulated by phosphorylation at serine 9.
Although PKB can phosphorylate GSK-3 at this site and
inhibit its activity, our results also implicate a direct role
for ILK in the regulation of GSK-3 activity. To determine
if ILK can directly phosphorylate GSK-3, we coincubated
ILK purified from serum-starved PC3 cells by immunopre-
cipitation with anti-ILK antibody with purified GSK-3-KD
in the presence of [ -32P]ATP and kinase reaction buffer.
As shown in Fig. 4 B, top, GSK-3 was successfully phos-
phorylated by the immunoprecipitated ILK and this phos-
phorylation was significantly inhibited in the presence of
the ILK inhibitor KP-SD-1 (Persad et al., 2001), demon-
strating the specificity of the phosphorylation of GSK-3 by
ILK. Although it is conceivable that PKB, which may have
coimmunoprecipitated along with ILK, is responsible for
Figure 4. (A) Bar graph represents quantification of GSK-3 ki-
nase activities by densitometric analysis (Odu/mm2) in PC3 cells
transiently transfected with empty vector (control), ILK-WT
(78%), ILK-KD (79%), PKB-AAA (79%), or PTEN-WT (82%).
Values in brackets indicate the transfection efficiency of the vari-
ous plasmids. Top panel is a representative autoradiograph of
GSK-3 kinase activities in the various transfectants. To evaluate
stimulation of GSK-3 activity, transfected cells were serum
starved for 18 h, refed with serum for 1 h, and then analyzed for GSK-3 kinase activity by using GS-1 peptide as a substrate. Although
PTEN and ILK-KD induced a dramatic increase in GSK-3 kinase activity ( 3–4-fold) the effect of PKB-AAA was more modest ( 1.6-
fold). GSK-3 kinase activity was determined as described in Materials and Methods. Immunoblot with anti–GSK-3 antibody shows
equivalent amounts of GSK-3 in each extract (bottom). (B) Bar graph represents quantification of ILK kinase activity by densitometric
analysis (Odu/mm2) in serum-starved (18 h) PC3 cells. ILK, purified by immunoprecipitation with anti-ILK antibody, was coincubated
with purified GSK-3-KD and [ -32P]ATP in the presence or absence of the ILK inhibitor KP-SD-1. Bottom panel represents an in vitro
ILK kinase assay, where recombinant ILK prepared in insect cells was coincubated with GSK-3-KD and ATP in the presence or ab-
sence of an ILK inhibitor, KP-SD-1. Phosphorylated GSK-3 was detected by Western blot analysis using anti–GSK-3-Ser-9-P antibody.
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the GSK-3 phosphorylation, the inhibitory effect of the
ILK inhibitor, KP-SD-1 argues against this. KP-SD-1 is in-
effective in inhibiting the activity of purified PKB in vitro
(Persad et al., 2001). This is further supported by an in
vitro kinase assay that shows that ILK can directly phos-
phorylate GSK-3 at serine 9 in the absence of PKB. This
was done by using recombinant ILK protein prepared in
insect cells, purified GSK-3-KD as the substrate, and ATP
as the phosphate group donor, followed by Western blot-
ting with anti–GSK-3-Ser-9-P antibody. As shown in Fig. 4
B, bottom, ILK can indeed promote the direct phosphory-
lation of GSK-3 on serine 9 and this phosphorylation is in-
hibited in the presence of the ILK inhibitor, KP-SD-1.
PTEN Stimulates Phosphorylation of  -Catenin 
and Accelerates Its Degradation
We examined the effect of PTEN on the stability of  -cat-
enin by pulse–chase analysis of PC3 cells transfected with
PTEN. We observed that the rate of degradation of  -cate-
nin was dramatically increased upon reexpression of
PTEN in these PTEN null cells (Fig. 5 A).
Since degradation of  -catenin is initiated by the phos-
phorylation of this protein at serine 33/37 and threonine 41,
we evaluated phosphorylation of  -catenin in PC3 cells
transfected with empty vector (control) or increasing
amounts of PTEN using antiphospho- -catenin-Ser 33/37/
Thr41 antibody (Fig. 5 B). Our results show that the phos-
phorylation of  -catenin at Ser 33/37 and Thr 41 is stimulated
with increasing quantities of PTEN transfected into the cells.
Inhibition of Serum-independent Cyclin D1 Expression 
in PTEN-negative Cells by PTEN-WT, Dominant 
Negative ILK, and GSK-3-WT
We have shown previously that reexpression of PTEN-
WT in PTEN null cells induces G1/S cell cycle arrest (Per-
sad et al., 2000). Since cyclin D1 has been established as a
target for  -catenin, our next aim was to examine the sta-
tus of this cyclin in PTEN null cells. As shown in Fig. 6, the
expression level of cyclin D1 is high in PC3 cells, and is se-
rum-independent. When these cells are transfected with
PTEN-WT, the expression of cyclin D1 is significantly in-
hibited. Consistent with our earlier finding that ILK is in-
hibited by PTEN (Morimoto et al., 2000; Persad et al.,
2000), transfection of dominant negative ILK also resulted
in profound inhibition of the expression of cyclin D1 (Fig.
6). Transfection of ILK-WT did not alter the expression of
this cyclin, demonstrating the specificity of the dominant
negative effect of ILK-KD. In agreement with the fact that
cellular  -catenin levels are regulated by GSK-3, the ex-
pression of cyclin D1 is also decreased dramatically by
transfection of GSK-3-WT (Fig. 6). A surprising observa-
tion in this study was the fact that transfection with PTEN-
WT, ILK-KD, or GSK-3-WT in PTEN null PC3 cells (Fig.
6) did not alter the expression level of the cyclin-depen-
dent kinase (CDK) inhibitors p27Kip and p21Cip. This is in
contrast to the findings of Sun et al. (1999), who reported
that PTEN appears to regulate the levels of CDK inhibi-
tors in PTEN /  ES cells.
Collectively, the results shown in Fig. 6 demonstrate that
PTEN and ILK regulate cyclin D1 expression via GSK-3.
Similar findings have recently been reported for mammary
carcinoma cells (D’Amico et al., 2000). Dysregulation of
cyclin D1 expression in PTEN mutant cells can be restored
by either inhibiting ILK, replacing PTEN, or augmenting
GSK-3 expression. Furthermore, the data indicate that
PTEN and ILK regulate the expression of cyclin D1 in a
parallel manner to their regulation of  -catenin.
Transcriptional Regulation of Cyclin D1 
Expression by PTEN, ILK, and GSK-3
Since  -catenin regulates cyclin D1 expression at the tran-
scriptional level and PTEN, ILK, and GSK-3 regulate  -cat-
enin, we measured cyclin D1 promoter activity by transiently
cotransfecting PC3 cells with a plasmid containing the cyclin
D1 promoter and a luciferase reporter gene with these ele-
ments of the PTEN/PI-3-kinase pathway. The cyclin D1 re-
porter gene was cotransfected with empty vector (control),
ILK-WT, ILK-KD, PTEN-WT, or GSK-3-WT and the cy-
clin D1 promoter activity was evaluated. As shown in Fig. 7
A, the cyclin D1 reporter gene activity is constitutively ele-
vated in the control PC3 cells in the absence and presence of
serum. Cotransfection of ILK-WT does not further enhance
the cyclin D1 promoter gene activity in these cells. However,
PTEN or dominant negative ILK imposes a substantial inhi-
bition of the cyclin D1 promoter activity. Interestingly,
cotransfection of GSK-3-WT resulted in an inhibition of the
cyclin D1 promoter activity by a similar magnitude to that
observed due to PTEN-WT or ILK-KD. It should be
pointed out that the transfection efficiency of all the plas-
mids was very similar and the enhancement of the endoge-
nous levels of proteins due to transfection of the respective
plasmids is quite comparable (Fig. 7 A).
Northern blot analysis of total RNA from serum-starved
PC3 cells was used to determine the effects of dominant
negative ILK, PTEN-WT, and GSK-3-WT on cyclin D1
transcriptional expression. As shown in Fig. 7 B, transfec-
tion of PC3 cells with ILK-KD, PTEN-WT, or GSK-3-WT
results in a dramatic decrease in transcriptional expression
of cyclin D1.
These results indicate that PTEN and ILK are linked in
a common pathway that regulates cyclin D1 gene tran-
scriptional activity. The fact that GSK-3 inhibits the cyclin
D1 promoter activity by a similar degree to that observed
due to PTEN-WT and dominant negative ILK indicates
that GSK-3 is very likely the downstream effector of ILK
via which this regulation of the cyclins is achieved.
Discussion
Dysregulated   -catenin expression and signaling is now
recognized as an important event in the genesis of several
malignancies, especially in colorectal cancer (Voeller et
al., 1998; Morin, 1999).  -Catenin mutations (Morin, 1999)
or loss-of-function mutations (Brabletz et al., 2000) of the
APC tumor suppressor gene appear to be crucial steps in
the progression of this disease. In this study, we have dem-
onstrated elevated levels of nuclear  -catenin in prostate
cancer cells PC3 and LNCaP, where mutations in  -cate-
nin (Voeller et al., 1998) or APC (Suzuki et al., 1994; Wa-
tanabe et al., 1996) are not known to be present. Instead,
these cells do not express the tumor suppressor PTEN
(Stambolic et al., 1998; Sun et al., 1999). In this study wePersad et al. Regulation of  -Catenin by PTEN 1169
demonstrate that the reexpression of PTEN in these cells
leads to a reduction of nuclear  -catenin, indicating the
regulation of the protein by the PTEN/PI-3 kinase path-
way. The fact that dominant negative ILK-KD also has a
similar effect on nuclear  -catenin expression and its func-
tion, as does PTEN, indicates that ILK is an important in-
termediate in this pathway. Since the dominant negative
ILK-KD can inhibit PKB phosphorylation and activity in
PC3 cells (Persad et al., 2000), and since PKB can phos-
phorylate and inactivate GSK-3 (Cross et al., 1995), it was
necessary to evaluate the PKB dependence of PTEN- and
ILK-mediated regulation of GSK-3 and subsequently  -cat-
enin. Our data, using a dominant negative form of PKB,
PKB-AAA (Wang et al., 1999), suggest that the effect of
PKB upon GSK-3 activity, nuclear  -catenin expression,
and TCF promoter activity are minor compared with the
effects of PTEN-WT, ILK-KD, or GSK-3-WT. These re-
sults suggest that although PTEN and ILK-KD inhibit
PKB phosphorylation and activation in PC3 cells (Persad
et al., 2000), this inhibition of PKB activity contributes less
to GSK-3 phosphorylation and activity in these cells than
does inhibition of ILK. This would imply that ILK can di-
Figure 5. PTEN stimulates
phosphorylation of  -cate-
nin and enhances its rate of
degradation. (A) PC3 cells
transfected with empty vec-
tor (control) or PTEN were
starved with DME without
cysteine and methionine,
pulsed with [35S]promix for
1 h, and then chased for the
indicated time-points with
cold DME containing cys-
teine/methionine and FBS.
Cells were then harvested,
lysed, and immunoprecipi-
tated for  -catenin. Results
were analyzed by densitome-
try and expressed as a percent-
age of the value at 0 h. (B) In
correlation with the enhanced
degradation of  -catenin on
reexpression of PTEN in PC3
cells, the phosphorylation at
ser33/37 and thr41 of  -cate-
nin also increases with trans-
fection of increasing amounts
of PTEN into PC3 cells.The Journal of Cell Biology, Volume 153, 2001 1170
rectly regulate GSK-3 phosphorylation and activity. In-
deed, it has been demonstrated previously that ILK can
phosphorylate GSK-3 in vitro (Delcommenne et al., 1998)
and that it can regulate GSK-3 activity in a PKB-indepen-
dent manner (Troussard et al., 1999); here we have dem-
onstrated that ILK can phosphorylate GSK-3 on serine 9
in the absence of PKB.
Regulation of  -catenin by GSK-3 (Morin, 1999; Beh-
rens, 2000), as well as regulation of GSK-3 by ILK in a PI-3
kinase–dependent manner, has been described (Troussard
et al., 1999; Tan et al., 2001). However, the regulation of
 -catenin by the PTEN/PI-3 kinase pathway is a novel find-
ing in this study that has not been described before. Hypo-
thetically, the reduction in nuclear  -catenin can lead to re-
duced complex formation with TCF, resulting in decreased
transactivation of genes containing the TCF-4/LEF-1 bind-
ing sequence near their promoter, such as cyclin D1
(Morin, 1999; Shtutman et al., 1999; Behrens, 2000; Lin et
al., 2000). This theory is supported by our finding that reex-
pression of PTEN in PTEN null PC3 cells resulted in re-
duced activation of the TCF promoter–reporter construct,
TOPFLASH. In addition, the fact that binding of nuclear
proteins to a TCF-4 oligonucleotide was reduced upon re-
expression of PTEN in PC3 cells supports this finding. The
fact that both PTEN and ILK-KD inhibited  -catenin con-
taining nuclear complex formation with TCF-oligonucle-
otide lends additional support to this hypothesis.
Mechanistically, our results indicate that PTEN induces
an increase in the phosphorylation of  -catenin, thereby in-
creasing its relative rate of degradation in PTEN-trans-
fected PC3 cells compared with the control cells. It is likely
that this increased phosphorylation is a direct result of the
observed increase in GSK-3 activity induced by PTEN. It is
well known that  -catenin stability is regulated by phos-
phorylation of the protein at Ser 33/37/45 and Thr 41 by
GSK-3 at its NH2 terminus (Yost et al., 1996), followed by
ubiquitination proteasome-mediated degradation. This in-
creased degradation of  -catenin may effectively lower cel-
lular concentration of the protein and prevent its further
accumulation in the nucleus, leading to decreased nuclear
 -catenin. It is also possible that PTEN may regulate the
translocation of  -catenin from the nucleus and subse-
quently induce its degradation in the cytosol. However, fur-
ther studies are required to explore this latter hypothesis.
PTEN-transfected PC3 cells also appear to exhibit a
more prominent membranal localization of  -catenin. This
may be related to the fact that PTEN appears to induce the
transcription of E-cadherin in PC3 cells which do not nor-
mally express E-cadherin (Davies et al., 2000). Also, it is
possible that the reexpression of E-cadherin in PC3 cells
may contribute to the observed decrease in nuclear  -cate-
nin.  -Catenin is known to interact with the cytoplasmic
domains of E-cadherin, linking it to the actin cytoskeleton
(Sadot et al., 1998; Shtutman et al., 1999). Thus, the more
prominent localization of  -catenin to the cell surface may
be related to the reappearance of its cell membrane an-
chor, E-cadherin, in the PTEN-reexpressing cells. How-
ever, we were unable to detect any E-cadherin– -cate-
nin complexes in PTEN-transfected PC3 cells (data not
shown). Also, the lack of interaction between  -catenin
and E-cadherin demonstrates that stimulation of E-cad-
herin expression is unlikely to play a significant role in the
observed decreased expression of nuclear  -catenin. How-
ever, it should be noted that PC3 cells do express N-cad-
herin (Tran et al., 1999) and this expression is unaffected
by reexpression of PTEN. Loss of E-cadherin expression
has been linked to the acquisition of an invasive and/or
metastatic phenotype (Bussemakers et al., 2000; Mialhe et
al., 2000) and it is this antiinvasive and/or antimetastatic
Figure 6. Alteration in the expression level of cyclin D1 and the
cyclin-CDK inhibitory proteins p27Kip and p21Cip, in serum-
starved PC3 cells transiently transfected with empty vector (con-
trol), ILK-WT (78%), ILK-KD (79%), PTEN-WT (82%), or
GSK-3-WT (78%). Values in brackets indicate the transfection
efficiency of each plasmid measured as described in Materials
and Methods. Cells transfected with the various plasmids were
deprived of serum for 18 h, commencing 48 h posttransfection.
Equal amounts of protein from the various treatments were then
analyzed for cyclin D1, p27Kip, and p21Cip expression by Western
blot using the respective antibodies. Although cyclin D1 expres-
sion is constitutively elevated in a serum-independent manner in
PC3 cells transfected with either empty vector or ILK-WT, it was
decreased in cells transfected with ILK-KD, PTEN-WT, or GSK-
3-WT. The p27Kip and p21Cip content was unaffected by all the
plasmid transfections. ILK-WT-V5,  ILK-KD-V5, PTEN-WT-
GFP, and GSK-3-WT-HA transgene expressions were deter-
mined in the transfectants by Western blot analysis with anti-V5,
anti-GFP, and anti-HA antibodies, respectively.Persad et al. Regulation of  -Catenin by PTEN 1171
property of E-cadherin that may be of significance in rela-
tion to the tumor suppressor PTEN. In support of this, re-
expression of E-cadherin by transfection has been shown
to suppress the invasive phenotype in E-cadherin–negative
prostate tumor cell clones (Luo et al., 1999). Overexpres-
sion or constitutive activation of ILK has been shown to re-
sult in an invasive phenotype concomitant with downregu-
lation of E-cadherin expression, translocation of  -catenin
to the nucleus, and formation of the LEF-1– -catenin bi-
partite complex (Novak et al., 1998; Tan et al., 2001). Also,
ILK has been shown to be regulated by the tumor suppres-
sor PTEN (Morimoto et al., 2000; Persad et al., 2000).
Cyclin D1 is known to be one of the oncogenic targets of
 -catenin (Morin, 1999; Shtutman et al., 1999; Behrens,
2000; Brabletz et al., 2000; Lin et al., 2000). We have demon-
strated that in PC3 cells, the expression level of cyclin D1 is
upregulated in a constitutive, serum-independent manner.
More importantly, replacement of PTEN or inhibition of
ILK results in dramatic suppression of the expression levels
of cyclin D1. Furthermore, transient overexpression of
GSK-3-WT also suppresses cyclin D1 expression. These re-
sults are supported by our previous observation that overex-
pression of ILK stimulates cyclin D1 expression (Radeva et
al., 1997). Also, ILK has been shown recently to regulate cy-
clin D1 transcription via a pathway involving GSK-3 and the
cyclic AMP response element binding protein transcription
factor (D’Amico et al., 2000). We note that cyclin D1 ex-
pression in PC3 cells changes in a parallel manner to  -cate-
nin expression in response to reexpression of PTEN or ex-
pression of ILK-KD and GSK-3. Therefore, we propose
that the alterations in cyclin D1 expression very likely repre-
sent the physiological end result of the regulation of  -cate-
nin by PTEN and ILK via GSK-3. It should be pointed out
that although nuclear  -catenin and cyclin D1 expressions
undergo parallel alterations due to reexpression of PTEN or
inhibition of ILK, the expression of the CDK inhibitors
p27Kip and p21Cip remain unchanged. This illustrates the
specificity of the alterations induced upon  -catenin and cy-
clin D1. Our hypothesis is confirmed by cotransfection ex-
periments with either TOPFLASH or the cyclin D1 pro-
Figure 7. (A) Transcription of cyclin D1 is inhib-
ited by PTEN-WT, ILK-KD, and GSK-3. Effect
of PTEN, ILK, and GSK-3 on cyclin D1 promoter
activity. PC3 cells were cotransfected with
pGL3-cyclin D1 and empty vector, ILK-WT,
ILK-KD, PTEN-WT, or GSK-3-WT. Cells were
serum starved for 18 h commencing 48 h post
transfection, refed with serum for 1 h, lysed, and
assessed for cyclin D1 activity by a luciferase re-
porter gene assay. Bar graph demonstrates that
cyclin D1 promoter activity is significantly re-
duced by comparable magnitude by the reex-
pression of PTEN or expression of ILK-KD and
GSK-3-WT. Bottom panels show the compara-
ble enhancement of the expression of ILK,
PTEN, and GSK-3 upon transfection of ILK-WT
or ILK-KD, PTEN-WT, and GSK-3-WT, respec-
tively. (B) Northern blot of cyclin D1 in serum-
starved PC3 cells. Total RNA was prepared by
the TRIZOL method from serum-starved PC3
cells transfected with empty vector (control),
ILK-KD, PTEN-WT, and GSK-3-WT. Tran-
scriptional expression determined by probing the
blot with a cyclin D1 probe randomly labeled
with [32P]dCTP demonstrated highly comparable
reductions due to transfection of PTEN, ILK-
KD, or GSK-3-WT.The Journal of Cell Biology, Volume 153, 2001 1172
moter luciferase reporter gene. The results clearly show that
PTEN, ILK-KD, and GSK-3-WT all dramatically reduce
both TOPFLASH and the cyclin D1 promoter activity by a
comparable degree. Furthermore, Northern blot analysis
demonstrates that ILK-KD, PTEN-WT, and GSK-3 induce
dramatic inhibitory effects upon cyclin D1 transcriptional
expression. This supports our working hypothesis that
PTEN and ILK can regulate nuclear  -catenin through
GSK-3. This is in agreement with the fact that  -catenin is
known to be regulated by GSK-3 (Morin, 1999; Behrens,
2000) and recent studies have identified GSK-3 as a critical
regulatory component for the transcriptional activity and
binding of the TCF–LEF-1– -catenin complex (Eastman
and Grosschedl, 1999) transcription factors.
In conclusion, we have demonstrated a novel pathway
involving PI-3 kinase/PTEN, ILK, and GSK-3 that main-
tains tight control over the levels and localization of  -cate-
nin (Fig. 8). In prostate cancer cells, as well in other malig-
nancies where PTEN is either lost or inactive, this control
may be eliminated, resulting in elevated  -catenin levels,
its accumulation in the nucleus, and increased transcrip-
tion of its oncogenic targets. Cyclin D1 is a known target
of  -catenin and it is also the first participant of the chain
of cyclins and CDKs that control progression through the
G1 and S phase of the cell cycle. Therefore, it is conceiv-
able that PTEN and ILK, by virtue of their capacity to reg-
ulate   -catenin and subsequently cyclin D1, may ulti-
mately regulate the progression of cells through the cell
cycle. By virtue of their ability to regulate the expression
of E-cadherin, PTEN/PI-3 kinase and ILK may also con-
trol the metastatic potential of cancer cells. Therefore, the
inhibition of a potent regulator such as ILK may present a
feasible alternative means of treating the numerous forms
of tumors where the PI-3 kinase–dependent signal trans-
duction pathway is dysregulated due to mutations of the
tumor suppressor PTEN.
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